[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644063":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":29,"responsibleParty":45,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":10,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Long-term survival (LTS) group",null,"patients with overall survival of more than 5 years after initial immunotherapy",{"label":13,"type":10,"description":14,"interventionNames":10},"Short-term survival (STS) group","patients with overall survival of less than 1 year after initial immunotherapy",[16],{"name":17,"affiliation":5,"role":18},"Jie Wang, MD, PhD","PRINCIPAL_INVESTIGATOR",[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Jie Wang, MD,PhD","CONTACT","8610-87788029","zlhuxi@163.com",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"Jie Zhao, MD","17801204737","zhaojie_12@163.com",[30],{"facility":31,"status":32,"city":33,"state":10,"zip":10,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Cancer Hospital Chinese Academy of Medical Sciences","RECRUITING","Beijing","China","CN",{"type":37,"coordinates":38},"Point",[39,40],116.39723,39.9075,{"lat":40,"lon":39},[43,44],{"name":17,"role":22,"phone":23,"phoneExt":10,"email":24},{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},{"type":18,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Jie Wang","Chief of Medical Oncology","100644063","characterization-of-multi-omics-landscapes-and-ai-pathological-prediction-model-for-long-term-survival-in-nsclc-immunotherapy-100644063",false,"NCT07668037","Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy","Characterization of Multi-Omics Landscapes in Long-Term Survival Following Immunotherapy and Development of an AI Pathological Prediction Model for Long-Term Survival Based on H&E-Stained Images in Advanced Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Patients with pathologically confirmed advanced or locally advanced non-small cell lung cancer (NSCLC).\n* Patients derived from real-world data of multiple centers (including Cancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital of Shanxi, Chinese Academy of Medical Sciences \\[Shanxi Cancer Hospital\\]; and other participating centers) or from completed phase III clinical trials (e.g., Choice-01, Rationale-307, Rationale-304).\n* Patients who received first-line or later-line immune checkpoint inhibitor (ICI) monotherapy or ICI-based combination therapy.\n* Patients with complete clinical information and available follow-up data.\n\nExclusion Criteria:\n\n* Patients whose systemic therapy did not include an immunotherapy regimen.\n* Patients lost to follow-up.","ALL","18 Years",{"count":58,"type":59},600,"ESTIMATED","OBSERVATIONAL","This study is a retrospective, multicenter, observational cohort study in patients with advanced or locally advanced non-small cell lung cancer (NSCLC). The aim of this study was to establish a long-term survival (LTS) versus short-term survival (STS) real-world cohort, to systematically characterize the multi-omics landscapes, and to develop and validate an artificial intelligence (AI) pathological prediction model based on routine H\\&E-stained images for predicting immune microenvironment features and long-term survival outcomes following immunotherapy.",[63,64,65],"Non-Small Cell Carcinoma of Lung","Immunotherapy","Advanced Non-Small Cell Lung Cancer","2026-06-22",{"date":68,"type":69},"2026-06-25","ACTUAL",{"date":71,"type":69},"2026-05-01",{"date":73,"type":59},"2030-05-01",{"name":5,"class":6},1]